Cantor Fitzgerald Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its price target increased by Cantor Fitzgerald from $47.00 to $80.00 in a report released on Thursday, Marketbeat.com reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on QURE. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price for the company in a research report on Thursday, August 14th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Wednesday. Chardan Capital lifted their target price on shares of uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim lifted their target price on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Leerink Partners boosted their price objective on shares of uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $64.64.

uniQure Trading Up 10.8%

Shares of uniQure stock opened at $52.65 on Thursday. uniQure has a 1 year low of $4.45 and a 1 year high of $54.98. The firm has a market cap of $2.89 billion, a PE ratio of -13.43 and a beta of 0.14. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The company has a 50 day simple moving average of $16.65 and a two-hundred day simple moving average of $14.61.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. Analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. Sanders Morris Harris LLC increased its stake in shares of uniQure by 12.5% in the first quarter. Sanders Morris Harris LLC now owns 114,887 shares of the biotechnology company’s stock worth $1,139,000 after buying an additional 12,783 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock worth $3,550,000 after buying an additional 261,323 shares during the period. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure in the first quarter worth $106,000. Diamond Hill Capital Management Inc. increased its stake in shares of uniQure by 22.8% in the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company’s stock worth $876,000 after buying an additional 15,333 shares during the period. Finally, XTX Topco Ltd increased its stake in shares of uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock worth $392,000 after buying an additional 20,720 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.